ipatasertib + docetaxel

Ipatasertib + docetaxel is a combination therapy consisting of **ipatasertib**, an oral, selective, ATP-competitive inhibitor of **AKT (protein kinase B)**, and **docetaxel**, an intravenous chemotherapeutic agent classified as a taxane that acts as a microtubule inhibitor. Ipatasertib targets the PI3K/AKT signaling pathway, which is frequently dysregulated in human cancers, especially those with PTEN loss, leading to unregulated cell proliferation and survival. Docetaxel stabilizes microtubules and inhibits their depolymerization, disrupting cell division. The combination aims to leverage potential synergy, as AKT inhibition can sensitize tumor cells to chemotherapy. Clinical trials are evaluating this combination primarily in advanced solid tumors, metastatic non-small cell lung cancer (NSCLC), and metastatic castration-resistant prostate cancer (mCRPC)[1][2][5].